Boardroom Alpha
S-1 primary document
BCTX · Registration Statement (Form S-1) · Filed December 23, 2025

Briacell Therapeutics CorpS-1 exhibit

ex107.htm

 

Exhibit 107

 

Calculation of Filing Fee Tables

 

FORM S-1

(Form Type)

 

BRIACELL THERAPEUTICS CORP.

(Exact Name of Registrant as Specified in its Charter)

 

Table 1: Newly Registered Securities

 

   Security Type  Security Class Title  Fee Calculation Rule  Amount Registered    Proposed Maximum Offering Price Per Share       Maximum Aggregate Offering Price(1)     Fee Rate   Amount of Registration Fee 
Fees to Be Paid  Equity  Units consisting of (1)(2)  457(o)            $25,000,000   $0.00013810   $3,452.50 
Fees to Be Paid  Equity  (i) Common Shares, no par value  457(o)             -    0.00013810-    0- 
Fees to Be Paid  Equity  (ii) One Warrant to Purchase One Common Share (3)  457(o)              -    0.00013810-    0- 
Fees to Be Paid  Equity  Common Shares Underlying Warrants  457(o)            $32,812,500(4)  $0.00013810    4,531.40 
Fees to Be Paid  Equity  Pre-funded Units consisting of (1)(2)  457(o)              -    0.00013810-    0(2)
Fees to Be Paid  Equity  (i) Common Shares (3)  457(o)             -    0.00013810-    0- 
Fees to Be Paid  Equity  (ii) Pre-Funded Warrants to Purchase Common Shares (3)  457(o)             -    0.00013810-    0(2)
Fees to Be Paid  Equity  Common Shares Underlying Pre-Funded Warrants (2)  457(o)             -    0.00013810-    0(2)
Fees to Be Paid  Equity  Placement Agent Warrants to Purchase Common Shares  457(o)             -    0.00013810-    0(3)
   Total Offering Amounts             57,812,500        $7,983.90 
   Total Fees Previously Paid             -        $- 
   Total Fee Offsets             -        $- 
   Net Fee Due             7,983.90        $7,983.90 

 

(1) This registration statement also includes an indeterminate number of securities that may become offered, issuable or sold to prevent dilution resulting from stock splits, stock dividends and similar transactions, which are included pursuant to Rule 416 under the Securities Act of 1933, as amended (the “Securities Act”).
   
(2) The proposed maximum aggregate offering price of the Units will be reduced on a dollar-for-dollar basis based on the offering price of any Pre-funded Units issued in the offering, and the proposed maximum aggregate offering price of the Pre-funded Units to be issued in the offering will be reduced on a dollar-for-dollar basis based on the offering price of any Units issued in the offering. Accordingly, the proposed maximum aggregate offering price of the Units and Pre-funded Units (including the common stock issuable upon exercise of the pre-funded warrants), if any, is $25,000,000.
   
(3) No separate registration fee is payable pursuant to Rule 457(g) under the Securities Act.
   
(4) As estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(g) under the Securities Act, the proposed maximum aggregate offering price of the shares underlying the Warrants (including Placement Agent’s Warrants) is equal to $32,902,500 (which is equal to the proposed maximum aggregate offering price for the Units of $25,000,000 multiplied by 125% plus the maximum aggregate offering price of the shares underlying the Placement Agent’s Warrants).

N/A

 

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer